CO6501188A2 - Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 - Google Patents
Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1Info
- Publication number
- CO6501188A2 CO6501188A2 CO12033021A CO12033021A CO6501188A2 CO 6501188 A2 CO6501188 A2 CO 6501188A2 CO 12033021 A CO12033021 A CO 12033021A CO 12033021 A CO12033021 A CO 12033021A CO 6501188 A2 CO6501188 A2 CO 6501188A2
- Authority
- CO
- Colombia
- Prior art keywords
- modulators
- benzoquinazolina
- piranil
- receptos
- metil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención está dirigida a compuestos de piranilo arilo metilo benzoquinazolinona de fórmula (I) que son moduladores alostéricos positivos del receptor M1 y que son útiles en el tratamiento de enfermedades en donde está involucrado el receptor M1, como por ejemplo la enfermedad de Alzheimer, la esquizofrenia, y los trastornos del dolor y del sueño. La invención también está relacionada con composiciones farmacéuticas que comprenden los compuestos, y con el uso de los compuestos y composiciones en el tratamiento de enfermedades mediadas por el receptor M1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23845709P | 2009-08-31 | 2009-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6501188A2 true CO6501188A2 (es) | 2012-08-15 |
Family
ID=43628378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12033021A CO6501188A2 (es) | 2009-08-31 | 2012-02-24 | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 |
Country Status (27)
Country | Link |
---|---|
US (1) | US8846702B2 (es) |
EP (2) | EP2473048B1 (es) |
JP (1) | JP5658255B2 (es) |
KR (1) | KR101651312B1 (es) |
CN (1) | CN102480964B (es) |
AU (1) | AU2010286683B9 (es) |
BR (1) | BR112012003464B8 (es) |
CA (1) | CA2770480C (es) |
CO (1) | CO6501188A2 (es) |
CY (1) | CY1116452T1 (es) |
DK (1) | DK2473048T3 (es) |
ES (1) | ES2537979T3 (es) |
HK (1) | HK1208225A1 (es) |
HR (1) | HRP20150572T1 (es) |
HU (1) | HUE026296T2 (es) |
IL (1) | IL217638A (es) |
ME (1) | ME02151B (es) |
MX (1) | MX2012002583A (es) |
MY (1) | MY160075A (es) |
NZ (1) | NZ598462A (es) |
PL (1) | PL2473048T3 (es) |
PT (1) | PT2473048E (es) |
RS (1) | RS54051B1 (es) |
RU (1) | RU2507204C2 (es) |
SI (1) | SI2473048T1 (es) |
WO (1) | WO2011025851A1 (es) |
ZA (1) | ZA201201205B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5651708B2 (ja) | 2009-12-17 | 2015-01-14 | メルク・シャープ・エンド・ドーム・コーポレイション | キノリンアミド化合物m1受容体陽性アロステリックモデュレータ |
US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
WO2012158473A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
US9878989B2 (en) | 2015-06-26 | 2018-01-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
BR112018004719B1 (pt) * | 2015-09-10 | 2022-11-29 | Suven Life Sciences Limited | Composto fluoroindola e composição farmacêutica |
EP3366679B1 (en) | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2017151449A1 (en) * | 2016-03-04 | 2017-09-08 | Merck Sharp & Dohme Corp. | M1 receptor positive allosteric modulator compounds and methods of use thereof |
EP3612527B1 (en) | 2017-04-18 | 2022-07-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
AU2019351469A1 (en) | 2018-09-28 | 2021-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003A (en) * | 1851-03-25 | Improvement in scythe-tastenings | ||
CA2220509C (en) * | 1995-05-31 | 2005-07-05 | Eisai Co., Ltd. | Fused polycyclic heterocycle derivatives |
AU776608B2 (en) * | 1999-04-30 | 2004-09-16 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
US20030176454A1 (en) * | 2000-05-15 | 2003-09-18 | Akira Yamada | N-coating heterocyclic compounds |
US20060233843A1 (en) | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
AU2007265412A1 (en) * | 2006-06-28 | 2008-01-03 | Merck & Co., Inc. | Benzyl-substituted quinolone M1 receptor positive allosteric modulators |
ES2400695T3 (es) * | 2006-07-17 | 2013-04-11 | Amgen Inc. | Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38 |
NZ584425A (en) * | 2007-09-26 | 2012-03-30 | Celgene Corp | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
US8557832B2 (en) * | 2008-11-20 | 2013-10-15 | Merck Sharp & Dohme Corp. | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators |
JP2012518640A (ja) * | 2009-02-23 | 2012-08-16 | メルク・シャープ・エンド・ドーム・コーポレイション | ピラゾロ[4,3−c]シンノリン−3−オンM1受容体陽性アロステリックモジュレーター |
WO2010123716A1 (en) | 2009-04-20 | 2010-10-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
WO2011041143A1 (en) | 2009-10-01 | 2011-04-07 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
WO2011049731A1 (en) | 2009-10-21 | 2011-04-28 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
US8664387B2 (en) | 2009-12-14 | 2014-03-04 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone M1 receptor positive allosteric modulators |
GB0921949D0 (en) | 2009-12-16 | 2010-02-03 | Fujifilm Mfg Europe Bv | Curable compositions and membranes |
WO2011137049A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived m1 receptor positive allosteric modulators |
-
2010
- 2010-08-26 MY MYPI2012000722A patent/MY160075A/en unknown
- 2010-08-26 RS RS20150383A patent/RS54051B1/en unknown
- 2010-08-26 ES ES10812601.2T patent/ES2537979T3/es active Active
- 2010-08-26 EP EP10812601.2A patent/EP2473048B1/en active Active
- 2010-08-26 WO PCT/US2010/046733 patent/WO2011025851A1/en active Application Filing
- 2010-08-26 DK DK10812601.2T patent/DK2473048T3/en active
- 2010-08-26 RU RU2012112064/04A patent/RU2507204C2/ru active
- 2010-08-26 KR KR1020127005167A patent/KR101651312B1/ko active IP Right Grant
- 2010-08-26 ME MEP-2015-86A patent/ME02151B/me unknown
- 2010-08-26 EP EP15159929.7A patent/EP2915812A1/en not_active Withdrawn
- 2010-08-26 SI SI201030940T patent/SI2473048T1/sl unknown
- 2010-08-26 CN CN201080038600.7A patent/CN102480964B/zh not_active Expired - Fee Related
- 2010-08-26 PL PL10812601T patent/PL2473048T3/pl unknown
- 2010-08-26 CA CA2770480A patent/CA2770480C/en active Active
- 2010-08-26 HU HUE10812601A patent/HUE026296T2/en unknown
- 2010-08-26 NZ NZ598462A patent/NZ598462A/xx not_active IP Right Cessation
- 2010-08-26 PT PT108126012T patent/PT2473048E/pt unknown
- 2010-08-26 MX MX2012002583A patent/MX2012002583A/es active IP Right Grant
- 2010-08-26 AU AU2010286683A patent/AU2010286683B9/en not_active Ceased
- 2010-08-26 US US13/392,647 patent/US8846702B2/en active Active
- 2010-08-26 BR BR112012003464A patent/BR112012003464B8/pt not_active IP Right Cessation
- 2010-08-26 JP JP2012526961A patent/JP5658255B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-19 IL IL217638A patent/IL217638A/en not_active IP Right Cessation
- 2012-02-17 ZA ZA2012/01205A patent/ZA201201205B/en unknown
- 2012-02-24 CO CO12033021A patent/CO6501188A2/es active IP Right Grant
-
2015
- 2015-05-28 HR HRP20150572TT patent/HRP20150572T1/hr unknown
- 2015-06-19 CY CY20151100527T patent/CY1116452T1/el unknown
- 2015-09-11 HK HK15108922.9A patent/HK1208225A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
DOP2011000135A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
NI201200107A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
ECSP16025201A (es) | Profármacos de amidas de piridona útiles como moduladores de canales de sodio | |
CO6470866A2 (es) | Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos. | |
GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
CR20130580A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
CR20120262A (es) | Derivados de 2-amino-5,5-difluor-5,6-dihidro-4h-[1,3] oxazin-4-il)-fenil]-amida | |
ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
BR112014012056A8 (pt) | compostos farmacêuticos | |
CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. | |
CY1113759T1 (el) | Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
ECSP11010947A (es) | Compuestos n- sulfonamido pirazolil policíclicos | |
ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
ECSP10010247A (es) | Derivados heterocíclicos | |
WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
CO6541615A2 (es) | Tiazoles bicíclicos como moduladores alostéricos de receptores mglur5 | |
JO2919B1 (en) | Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor | |
UY31680A1 (es) | "agonistas de los receptores muscarínicos, composiciones, métodos de tratamiento en que se emplean y sus procesos de preparación-176" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |